drugset / Trial / NCT00430807

Hydroxychloroquine in Giant Cell Arteritis

NCT00430807

Phase 3 Completed 75 enrolled University Hospital, Toulouse
RandomizedParallel-groupTriple-blindTreatment

Summary

Cortico-dependence is frequent in giant cell arteritis patients, and no drugs has proved its ability to prevent corticodependence. Hydrocychloroquine is a well tolerated immunomodulatory drug that may have a corticosteroid sparing potential according to immuno-pharmacological and clinical data. We have designed a multcentric double blind versus placebo randomized controled trial to assess the corticosteroid sparing effect of hydroxychloroquine in non complicated giant cell arteritis.

Timeline

Start
2002-01
Primary completion
2005-01
Completion
2006-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxychloroquine Small molecule

Indications